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Aim of the study: PROFIL was a pro-
spective observational study conduct-
ed to investigate physicians’ evalu-
ation of febrile neutropenia (FN) risk 
and reasons for giving pegfilgrastim 
primary prophylaxis (PP) in routine 
clinical practice in Poland. 
Material and methods: Adult cancer 
patients treated with chemothera-
py (CT), assessed by investigators 
as having high overall FN risk, and 
who received pegfilgrastim in cycle 1 
were enrolled between 03/2009 and 
09/2010. Investigators assessed FN 
risk of the CT regimen, individual risk 
factors, and overall FN risk, and were 
asked to provide the most important 
reasons for providing pegfilgrastim 
PP. Investigator-assessed CT FN risk 
was compared with guideline classi-
fication. 
Results: Data were analysed from 
1006 breast, ovarian, and lung cancer, 
and non-Hodgkin (NHL) and Hodgkin 
lymphoma (HL) patients. The most im-
portant reasons for using pegfilgras-
tim PP were high CT FN risk and ad-
vanced disease; these were consistent 
across tumour types and treatment 
intent. The investigators generally as-
sessed high CT FN risk in agreement 
with guideline classification. Febrile 
neutropenia occurred in 4% of pa-
tients, most commonly in HL, NHL, and 
patients with advanced disease. 
Conclusions: High CT FN risk and ad-
vanced stage of disease were found 
to be the most important reasons for 
providing pegfilgrastim PP by physi-
cians in Poland.
Key words: febrile neutropenia, che-
motherapy, pegfilgrastim, GCSF, risk 
category.
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Introduction 
Febrile neutropenia (FN) is a serious side effect of myelosuppressive che-
motherapy (CT), carrying a high risk of mortality and typically requiring hos-
pitalisation with intensive treatment [1, 2]. As a consequence of FN, CT is 
often reduced or delayed [3, 4], and reduced relative dose intensity of CT 
potentially compromises the success of curative treatment [5, 6]. 
Prophylactic use of recombinant human granulocyte-colony stimulating 
factor (G-CSF) has been shown to reduce the incidence of CT-related FN [7], 
and guidelines recommend G-CSF primary prophylaxis (PP) in all patients 
with high (≥ 20%) overall FN risk [8–10]. High overall FN risk may arise from 
high-risk CT alone, or from intermediate-risk CT combined with individual 
risk factors (e.g. age ≥ 65 years, advanced disease, prior FN) [8–10].
Pegfilgrastim is a once-per-cycle G-CSF registered for prophylaxis of FN in 
patients receiving myelosuppressive CT [11]. A range of studies have indicat-
ed that PP with pegfilgrastim may provide better protection from FN than 
other approaches. For example, in a study of 1256 breast cancer patients 
receiving TAC, FN incidence was significantly lower with pegfilgrastim pro-
phylaxis (7%) than with ciprofloxacin (22%) or daily G-CSF prophylaxis on 
days 5–10 (18%) [12]. Furthermore, meta-analyses of clinical trials comparing 
pegfilgrastim with standard G-CSF [7, 13], and an integrated analysis com-
paring pegfilgrastim PP with current medical practice [14], have all shown 
the incidence of FN to be significantly lower with pegfilgrastim. Studies of 
clinical practice suggest that daily G-CSFs are often administered later in the 
CT cycle and for fewer days than recommended, resulting in an increased 
risk of hospitalisation for neutropaenic complications [15–22]. Current Euro-
pean guidelines advise that pegfilgrastim may avoid the problem of patients 
receiving suboptimal daily G-CSFs [8].
Except for when the CT regimen alone carries an FN risk ≥ 20%, the 
decision of whether to use G-CSF prophylaxis is based on the physician’s 
judgement of the combined impact of CT regimen myelotoxicity, individual 
risk factors, disease characteristics, and treatment intention [8–10]. Current 
guidelines provide no quantitative weighting of risk factors or simple algo-
rithms for calculating the combined risk. A number of models for predicting 
FN risk based on individual risk factors are available [23–29]; however, reli-
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able validation with independent data is required before 
they can be incorporated into guidelines.
The primary objective of the PROFIL study was to assess 
how physicians reach the decision to use pegfilgrastim for 
PP of FN in patients receiving anticancer CT in routine clin-
ical practice in Poland, and to determine the most import-
ant reasons for their decision. 
Material and methods
Study design 
This was a multicentre, prospective, observational study. 
According to local law, there was no requirement for eth-
ical approval. Compliance with local and international 
guidelines was assessed additionally to the study protocol.
The primary outcome was to identify the most im-
portant factors contributing to the decision to use peg-
filgrastim for PP of FN. Secondary outcomes included the 
following: the proportion of patients with dose reduction 
or delay, with administration of IV anti-infectives, who de-
veloped severe neutropenia (grade III/IV) or FN, who were 
hospitalised for FN or infections, or who experienced seri-
ous/non-serious adverse drug reactions (ADRs) suspected 
of being related to pegfilgrastim by the investigators.
Procedure and data collection
Eligible patients were adults treated with CT for breast, 
lung, or ovarian cancer, or lymphoma with a high overall 
risk of FN (≥ 20%), who received prophylactic pegfilgrastim 
according to the SmPC [11] in cycle 1 before study enrol-
ment. 
Data on patient and treatment characteristics were col-
lected at baseline. 
For the first cycle, investigators separately assessed CT 
FN risk, individual FN risk factors, and overall FN risk ac-
cording to EORTC guidelines [8], and provided reasons for 
pegfilgrastim PP (primary outcome). 
Individual FN risk factors were selected from the follow-
ing: age (≥ 65 years); advanced stage disease/metasta-
ses; planned antibiotic prophylaxis; previous FN episode; 
planned use of G-CSF; female gender; haemoglobin < 12 g/dl; 
cardiovascular disease; kidney disease; elevated liver en-
zymes; planned high dose intensity (≥ 80%); poor general 
condition and/or poor nutritional status; ≥ 1 comorbidity; 
body surface area < 2 m2; absolute neutrophil count (ANC) 
< 1.5 × 109/l before treatment; and albumin ≤ 3.5 g/dl. 
Factors were selected only if considered important by the 
investigator in their overall risk assessment (in some cas-
es the risk factor, although present, may not have been 
selected because it did not contribute to overall FN risk in 
the judgement of the investigator).
Reasons for pegfilgrastim PP were entered in order 
of importance into 3 separate fields, (Reasons 1, 2 and 
3), each with the following options: age ≥ 65 years; poor 
ECOG performance status; female gender; tumour type; 
advanced disease stage; CT regimen; previous FN episode; 
poor nutrition status; anaemia (haemoglobin < 12 g/dl); 
or cardiovascular, liver, or kidney disease. One, two, or all 
three fields could be used.
Data on outcomes (including FN, other neutropenia-re-
lated outcomes, and ADRs) were collected from the first 
CT cycle throughout treatment. Febrile neutropenia was 
defined as ANC < 0.5 ×  109/l, or < 1.0 × 109/l predicted to 
fall below 0.5 × 109/l within 48 hours, with fever (> 38.0°C 
sustained for at least 1 hour, or > 38.5°C obtained by a sin-
gle reading) or clinical signs of sepsis. Dose delays and re-
ductions were defined by investigators.
Statistical analyses
All parameters were evaluated descriptively. Quanti-
tative data were summarised by means, medians, rang-
es, and standard deviations. Categorical data were sum-
marised by the number and percentage in each category.
In a post-hoc analysis, CT FN risk was classified accord-
ing to EORTC, local, ASCO and NCCN guidelines, and pub-
lished literature [8–10] to enable comparison of investiga-
tor-assessed CT FN risk with that published in guidelines. 
A list of regimens and assigned FN risk categories accord-
ing to published guidelines is given in Supplementary On-
line Resource 1.
 
Results
Patient and treatment characteristics
Data from 1006 patients enrolled from 55 cancer treat-
ment centres in Poland between 03/2009 and 09/2010 
were analysed. In general, the patient population was rel-
atively young with good performance status (Table 1). The 
most common tumour type was breast (43%), followed by 
non-Hodgkin lymphoma (NHL; 26%). Overall, 76% of pa-
tients had advanced (stage III/IV) disease, with an even 
distribution between the two stages. Notably, lung cancer 
had a different patient distribution, with 81% having stage 
IV disease. Most patients with breast cancer, HL, and NHL 
received CT with curative intent; most patients with lung 
and ovarian cancer received CT with intent to prolong sur-
vival.
For each tumour type, most patients received specific 
CT regimens: breast cancer – 53% received AT or TAC; ovar-
ian cancer – 62% received a taxane-platinum combination; 
lung cancer – 69% received platinum-based CT; NHL – 65% 
received CHOP or CHOP-like CT; and HL – 46% received 
ABVD and 19% received escalated BEACOPP. Overall, 440 
patients (44%) received taxanes as monotherapy or in 
combination with other CT.
A significant proportion of patients (44%) received CT 
with high FN risk, according to guidelines. Ovarian cancer 
had the highest proportion of patients receiving regimens 
that were not classified in guidelines (20%). 
Investigator-assessed chemotherapy febrile 
neutropenia risk
Most patients received CT with an FN risk specified in 
guideline publications [8–10]; however, 119 patients re-
ceived regimens with no guideline-assigned FN risk (Sup-
plementary Online Resource 1).
Investigators generally assessed high FN risk CT in 
agreement with central guideline classification (Table 2). 
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For regimens with medium-to-low FN risk according to 
guidelines, physicians tended to rate the FN risk as higher 
than published. In 19% (82/442) of patients receiving CT 
with high FN risk according to guidelines, the CT FN risk 
was either not evaluated or was estimated as lower by in-
vestigators (Table 2).
Investigator-assessed overall febrile neutropenia risk
Of 1006 enrolled patients, 905 (90%) were assessed 
separately by investigators according to EORTC guidelines: 
an overall FN risk of ≥ 20% was confirmed in 797 (79% 
overall). For 692 patients (69% overall), this level of risk 
was attributed to the CT regimen alone, irrespective of 
other risk factors. However, for 105 patients (10% overall) 
the investigators judged that a combination of CT regi-
men and individual risk factors raised the overall FN risk 
to ≥ 20%.
Physicians were asked to select risk factors that con-
tributed to their overall FN risk assessment. The most fre-
quent risk factors chosen by investigators were: female 
gender (61%); planned CT dose intensity ≥ 80% (57%); 
advanced stage disease/metastases (52%); and planned 
antibiotic prophylaxis (36%). The least frequent risk fac-
tors were: albumin ≤ 3.5 g/dl (7%); ANC < 1.5 × 109/l before 
treatment (5%); planned use of G-CSF (4%); and kidney 
disease (3%).
Planned high dose intensity of CT (≥ 80%) was cited 
as an individual FN risk factor for 62% of patients treated 
with intention to cure but for only 27% of those receiving 
palliative treatment.
Investigator-assessed reasons for PP
The most important reason given by physicians for pro-
viding pegfilgrastim PP were planned high-risk CT, selected 
for 78% of patients overall and as the most important rea-
son in 72% or patients. The most frequent second and third 
most important reasons were advanced disease (28%) and 
female gender (17%), respectively. Reasons were general-
ly consistent across tumour types and treatment intent 
(Fig. 1). Although there was opportunity to provide up to 
Table 1. Patient and treatment characteristics
Breast
n = 431
Ovarian
n = 110
Lung
n = 108
NHL
n = 263
HL
n = 94
Total
n = 1006
Age, median (range) 53 
(20–86)
57 
(36–78)
60 
(21–81)
60 
(18–86)
35 
(18–73)
55 
(18–86)
Female (%) 100 100 39 46 49 74
ECOGa PS 0-1 (%) 94 95 66 65 81 82
Cancer stage (%)
  I
  II
  III
  IV
4
29
45
22
13
11
41
35
0
1
18
81
2
19
29
51
3
20
40
36
4
21
37
39
Treatment intent (%)
  Cure
  Prolong life
  Palliative
76
20
3
39
49
12
6
80
14
76
22
2
92
6
2
66
29
5
CT FN Riskb (%)
  < 10%
  10–19%
  ≥ 20%
  Not categorised
5
26
62
6
45
35
1
20
4
47
38
11
0
48
33
19
46
0
47
7
12
33
44
12
a PS, performance status
b Risk of FN due to CT regimen alone, according to published guidelines, as determined from post-hoc analysis 
Table 2. Comparison of investigator CT FN risk assessment with classification according to guidelines
CT FN risk according 
to guidelines
Investigators’ assessment of CT FN risk
Total, 
n
≥ 20% 
n (%)
10–19% 
n (%)
< 10% 
n (%)
Not evaluated 
 n (%)
≥ 20% 442 360 (81) 35 (8) 4 (1) 43 (10)
10–19% 327 199 (61) 88 (27) 14 (4) 26 (8)
< 10% 118 62 (53) 28 (24) 7 (6) 21 (18)
Not categorised 119 71 (60) 33 (28) 4 (3) 11 (9)
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three reasons, only one reason was given for 25% of pa-
tients, and two reasons were given for 50% of patients.
Incidence and consequences of febrile 
neutropenia
Overall, FN incidence was 4.4% (Table 3). Most FN cases 
were in HL and NHL patients, and FN incidence was high-
est in patients with advanced disease. Febrile neutropenia 
occurred in all three treatment-intention categories. Fe-
brile neutropenia incidence was higher in patients where 
poor general condition and/or poor nutritional status 
(12.4%), baseline albumin ≤ 3.5 g/dl (11.0%), or baseline 
ANC < 1.5 × 109/l (8.7%) contributed to physician overall FN 
risk assessment.
Of the 44 patients who experienced FN, 75% required 
hospitalisation and 50% experienced FN in CT cycle 1. In-
travenous anti-infectives were provided to 114 patients 
(11%) overall and to 27% of NHL patients. 
Dose reductions/delays
Dose reductions/delays occurred in 235 patients (23%) 
overall (lowest rate [16%] in breast cancer; highest rate 
[34%] in ovarian cancer). The rate in patients receiving 
palliative treatment was 35% (vs. 20% in patients treated 
with curative intent).
The most common reasons for dose reductions were 
haematological toxicities other than neutropenia (27%), 
non-haematological toxicities (26%), and poor general 
condition of the patient (23%).
Adverse drug reactions
Bone and joint/muscle pain were the most common 
ADRs (occurring in 57% and 56% of patients, respectively). 
One patient experienced a serious ADR (granulocytopae-
nia).
Discussion
The most important reasons for providing pegfilgrastim 
PP to reduce FN incidence in patients receiving antican-
cer CT in routine clinical practice in Poland were consis-
tent with the individual risk factors selected by physicians. 
Physicians considered the FN risk of planned CT as most 
important, followed by disease stage, and then female 
gender (probably because of the large proportion of breast 
cancer patients included).
The results of this study are corroborated by other 
studies: high FN risk of planned CT was the most common 
reason reported by physicians for pegfilgrastim use in an 
interim analysis of the DIEPP observational study [30], and 
female gender and advanced stage of disease were among 
the three most common individual FN risk factors consid-
ered by physicians in both the DIEPP and an Austrian ob-
servational study [30, 31]. Age >65 years was a common-
ly-selected risk factor in these two observational studies 
[30, 31], as recommended in current European guidelines 
[8]; however, this was less applicable to the younger pop-
ulation of the current study. Often, one or two of these 
reasons alone were sufficient to form a clear decision to 
provide pegfilgrastim PP. This was especially true in breast 
cancer and HL, where patients tended to be younger and 
more likely to receive CT with curative intent. Perhaps, in 
this setting, the need to provide the full dose of CT without 
delay simplifies the decision.
For CT regimens with high FN risk, the investigators of 
this study were generally in agreement with central guide-
line classifications, but there was a tendency for investi-
gators to rate the FN risk of other CT regimens as higher 
than published values. Although discrepancies between 
Fig. 1. Distribution of all reasons for pegfilgrastim PP in cycle 1
Total 
N = 3018
Total 
N = 1293
Total 
N = 330
Total 
N = 324
Total 
N = 789
Total 
N = 282
0 10 20 30 40 50 60 70 80 90 100
Proportion of all reasons given for pegfilgrastim PP in cycle 1, %
Planned CT with a high FN risk
2nd or 3rd reason not given
Advanced stage cancer
Female gender
CV, liver or kidbey disease
Age > 65 years
Previous episode of FN
Othera
26 25 15
10
12 21
13
12
22
13
17
16
22
19
21 6
7 7
6
6
7
8
19
12
9
28
22
23
21
29
29
23
19
24
27
Table 3. Febrile neutropenia incidence
Variable  Total 
evaluated
n
Number who experienced  
≥ 1 FN incident
n (% [95% CI])
All  1006 44 (4.37 [3.27–5.82])
Sex
  Female  
  Male  
747
259
22 (2.95 [1.95–4.42])
22 (8.49 [5.68–12.53])
Tumour type
  Lung
  Breast
  Ovarian
  HL
  NHL
108
431
110
94
263
0 (0 [0–3.43])
6 (1.39 [0.64–3])
0 (0 [0–3.37])
12 (12.77 [7.46–21])
26 (9.89 [6.84–14.09])
Cancer stage
  I
  II
  III
  IV
37
209
372
388
0 (0 [0–9.41])
6 (2.87 [1.32–6.12])
19 (5.12 [3.29–7.84])
19 (4.90 [3.16–7.52])
Treatment intention
  Cure
  Prolong life
  Palliative
664
293
49
30 (4.52 [3.18–6.38])
12 (4.1 [2.36–7.02])
2 (4.08 [1.13–13.71])
Overall FN risk
  ≥ 20%
  10–19%
  < 10%
  Risk not
  evaluated
797
101
7
101
3
7 (4.64 [3.39–6.33])
4 (3.96 [1.55–9.74])
0 (0 [0–35.43])
3 (2.97 [1.02–8.37])
aFor each tumour type, reasons with values ≤ 5% were grouped into “other” 
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guideline and investigator CT FN risk assessments might 
simply reflect a lack of awareness of the FN risk associated 
with some CT regimens, it is also possible that investiga-
tors were reflecting the likely FN incidence in their local pa-
tient population, which might differ from the populations 
enrolled in the original trials used as sources for guideline 
CT FN risks. Indeed, FN events are often underreported in 
clinical trials [32], and patient populations in clinical trials 
are likely to have fewer risk factors than the broader pop-
ulation. For example, current EORTC guidelines cite the FN 
risk of ABVD as 4% [8], based on clinical trial data [33], 
whereas FN rates as high as 11–12% [34] have been report-
ed in routine clinical practice. 
The assignment of CT FN risk was hampered by the lack 
of reliable data on the FN risks of many CT regimens in 
current use. The FN risk of 29 regimens used in this study, 
affecting 119 patients (12%), could not be validated by cur-
rent guidelines. Additional guidance from retrospective 
analyses of hospital claims data is limited by the lack of an 
ICD-9 code for FN, meaning that often only neutropaenia 
is reported, highlighting the need for continued efforts to 
provide clarity on the FN risk of CT regimens in current use.
It is also unclear how much individual FN risk factors 
contribute to overall FN risk. Work is currently underway 
to validate models for predicting FN risk based on individ-
ual risk factors using independent data sources [35], an 
important requirement if these models are to reliably pre-
dict overall FN risk in routine practice. Low albumin and 
ANC counts at baseline have previously been identified in 
FN risk models as potential predictors of FN occurrence 
but are not mentioned in the EORTC risk–assessment al-
gorithm [8, 24, 28]. In this study, both factors contributed 
infrequently to investigators’ overall FN risk assessments, 
but in patients for whom these factors were chosen FN in-
cidence was higher than in the total population, suggest-
ing that these factors are worthy of further study.
The consequences of FN were significant, with 75% of 
patients experiencing FN in this study requiring hospi-
talisation. Considering that this patient population was 
judged to be at ≥ 20% risk of FN, FN rates were low with 
pegfilgrastim PP (4% overall), as reported in other obser-
vational studies in which patients at high FN risk received 
pegfilgrastim [30, 31, 36]. Furthermore, the majority of 
dose delays that occurred were not neutropaenia related. 
Bone pain is common in patients receiving CT, with or 
without pegfilgrastim support, particularly in those who 
are young, have breast cancer, and receive taxanes [37, 38]. 
These characteristics were typical of many of the patients 
in this study (median age 55 years, 43% with breast cancer, 
44% received taxanes); it was therefore not surprising that 
bone pain and joint/muscle pain were the most common 
ADRs.
The findings of this observational study are limited by 
being purely descriptive, and, in addition, some features 
of the population (mostly young age, good performance 
status, large proportion with breast cancer) might have 
influenced the results. Comparisons between CT FN risk 
assessments made by investigators, and those from 
guidelines, should be taken in the context of the above 
discussion, relating to the potential influence of different 
patient characteristics and the setting of community prac-
tice versus clinical trials.
In conclusion, high CT FN risk and advanced stage dis-
ease were considered the most important reasons for pro-
viding pegfilgrastim. Febrile neutropenia incidence was 
relatively low (4%) in these high-risk patients with pegfil-
grastim PP.
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